COMMUNIQUÉS West-GlobeNewswire

Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.
30/05/2025
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 30, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ [...]
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers
30/05/2025
30 scientific abstracts will be presented using clonoSEQ for MRD assessment across multiple types of blood cancers SEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a [...]
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
30/05/2025
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis [...]
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics
30/05/2025
REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc., announced its name [...]
Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million
30/05/2025
ATLANTA, May 30, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio [...]
Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2025 MedTech Innovation Spotlight
30/05/2025
MINNEAPOLIS, May 30, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive [...]
Spectral AI Announces Appointment of Stanley Micek as Chief Operating Officer
30/05/2025
DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment [...]
EssilorLuxottica va acquérir les cliniques Optegra, une nouvelle étape clé dans sa stratégie med-tech
30/05/2025
EssilorLuxottica va acquérir les cliniques Optegra, une nouvelle étape clé dans sa stratégie med-tech Avec l’acquisition de cette plateforme d'ophtalmologie de premier plan auprès de MidEuropa, le Groupe vise à [...]
EssilorLuxottica to acquire Optegra clinics, another leap forward in its med-tech strategy
30/05/2025
EssilorLuxottica to acquire Optegra clinics, another leap forward in its med-tech strategy Acquisition of leading ophthalmology platform from MidEuropa will advance the Group’s development of the most comprehensive and [...]
Enterome presents positive Phase 1/2 MSS/pMMR metastatic colorectal cancer data in patients treated with EO4010 OncoMimics™ immunotherapy plus nivolumab at ASCO 2025
30/05/2025
Survival in 20 patients with MSS/pMMR mCRC at a median follow-up of 15.4 months was 40% at 12 months; median survival is currently 11.3 months Survival has currently reached plateau, with 34% (7/20) of patients still [...]
Le Québec a les cartes en main pour réduire les impacts des écrans sur la santé des jeunes
30/05/2025
MONTRÉAL, 30 mai 2025 (GLOBE NEWSWIRE) -- Après plusieurs mois de travaux et de consultations, la Commission spéciale sur les impacts des écrans et des réseaux sociaux sur la santé et le développement des jeunes (CSESJ [...]
Communiqué de presse : L’itépekimab a satisfait au critère d’évaluation principal dans l’une des deux études de phase 3 sur la BPCO
30/05/2025
L’itépekimab a satisfait au critère d’évaluation principal dans l’une des deux études de phase 3 sur la BPCO L’étude AERIFY-1 a atteint son objectif principal, à savoir une réduction statistiquement significative des [...]
Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies
30/05/2025
Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of [...]
Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis
30/05/2025
Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two years of treatment Phase III studies for fenebrutinib in relapsing and primary [...]
Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
30/05/2025
AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefit [...]
Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
29/05/2025
WESTLAKE VILLAGE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
Cytokinetics to Participate in the Jefferies Global Healthcare Conference
29/05/2025
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to participate in a fireside chat at [...]
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
29/05/2025
LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will present at the following investor conferences in June: Jefferies 2025 Global [...]
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
29/05/2025
SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems [...]

Pages